Nextbiomedical넥스트바이오메디컬
389650 · KOSDAQ · ₩389650 · 넥스트바이오메디컬
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
With these assumptions the model gives no positive value.
- Enterprise value
- −₩91B
- Equity value
- −₩75B
- WACC
- 7.4%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model gives no positive value at these assumptions. What we can see:
- To match today's price of ₩28,350, the model needs an operating margin of 57.1% every year (it uses −18.2%).
- In the projection, spending on equipment, software and working capital takes most or all of the after-tax operating profit, so free cash flow is thin. Companies that invest heavily often look like this until spending slows.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- —
- Base
- —
- Bull
- —
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (−18.2%).
Revenue growth
- 25%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (72.7% a year, annual reports), fading to 3% by year 5.
- 19.5%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (72.7% a year, annual reports), fading to 3% by year 5.
- 14%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (72.7% a year, annual reports), fading to 3% by year 5.
- 8.5%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (72.7% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (72.7% a year, annual reports), fading to 3% by year 5.
Business
- -18.2%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 9.5%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 11.9%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).
- 40%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.08%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-29.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.12, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.58%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩18B
- Net debt (borrowings and leases − cash and deposits)
- −₩16B
- Shares
- 8,277,286
- Share price
- ₩28,350
- Market cap
- ₩235B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|
| Revenue | ₩9.5B | ₩16B | ₩22B | ₩27B | ₩30B | ₩33B | ₩34B |
| Growth | — | 72.7% | 25.0% | 19.5% | 14.0% | 8.5% | 3.0% |
| EBIT | −₩3.6B | −₩720M | −₩4B | −₩4.8B | −₩5.5B | −₩6B | −₩6.2B |
| EBIT margin | −37.5% | −4.4% | −18.2% | −18.2% | −18.2% | −18.2% | −18.2% |
| After-tax EBIT | −₩2.6B | −₩522M | −₩2.9B | −₩3.5B | −₩4B | −₩4.3B | −₩4.5B |
| + Depreciation | — | — | ₩2.1B | ₩2.5B | ₩2.9B | ₩3.1B | ₩3.2B |
| − Capital spending | ₩439M | ₩3.2B | ₩2.6B | ₩3.2B | ₩3.6B | ₩3.9B | ₩4B |
| − Working capital | — | ₩9.8B | ₩1.8B | ₩1.7B | ₩1.5B | ₩1B | ₩394M |
| Free cash flow | — | — | −₩5.2B | −₩5.9B | −₩6.2B | −₩6.2B | −₩5.7B |
| Discount factor | — | — | 0.931 | 0.867 | 0.808 | 0.752 | 0.700 |
| Present value | — | — | −₩4.9B | −₩5.1B | −₩5B | −₩4.6B | −₩4B |
Terminal value −₩96B, worth −₩67B today: 74% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩5,939 a share)Now 4.77× | ₩33,2005.59× | ₩50,5148.50× | ₩80,47213.5× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2024, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.4% | — | — | — | — | — |
| 6.9% | — | — | — | — | — |
| 7.4% | — | — | — | — | — |
| 7.9% | — | — | — | — | — |
| 8.4% | — | — | — | — | — |
Now (TTM)
- Market cap
- ₩235B
- Enterprise value
- ₩218B
- P/E
- —
- P/B
- 4.8×
- P/S
- 13.2×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | |
|---|---|---|
| Price | ₩89,400 | ₩41,000 |
| Market cap | ₩740B | ₩339B |
| P/E | — | 118.7× |
| P/B | 15.4× | 7.5× |
| P/S | 44.9× | 35.6× |
| EV/EBITDA | — | — |
| Dividend yield | 0.0% | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Nextbiomedical | — | 4.8× | 13.2× | — | 0.0% |
| TSE | 27.5× | 6.1× | 5.1× | — | 0.2% |
| Kctech | 22.1× | 3.4× | 4.1× | 17.1× | 0.5% |
| Classys | 12.7× | 3.2× | 4.7× | 9.9× | 3.7% |
| Park Systems | 69.0× | 4.7× | 8.2× | — | 0.2% |
| DI | 42.2× | 5.8× | 2.6× | — | 0.6% |
| Curiox Biosystems | — | 21.3× | 182.0× | — | 0.0% |
| Similar companies (median) | 27.5× | 5.3× | 4.9× | 13.5× | 0.3% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Nextbiomedical / 넥스트바이오메디컬 / 389650 / KRX:389650
Source: KRX statistical information